Yang Yang

Dr. Yang Yang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2021 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
HCHui Chen
Hui Chen
CSChang Sun
Chang Sun
YWYang Wang
Yang Wang
XGXiaojiao Gao
Xiaojiao Gao
JYJinwei You
Jinwei You
XLXiaojun Li
Xiaojun Li
In December 2019, a severe acute respiratory syndrome caused by SARS-CoV-2 spread rapidly worldwide. Portable nucleic acid tests of SARS-CoV-2 are critically important for diagnostics. In this study, we used an isothermal amplification method—Multienzyme Isothermal Rapid Amplification (MIRA)—for rapid detection of SARS-CoV-2. We designed the primers and probes in ORF1ab and N gene of SARS-CoV-2. The amplicons could be monitored by lateral flow dipsticks (LFDs). The reaction temperature, time, concentrations of primers and probes, and working volume were optimized. Four commercial swab collection buffers were used to test the amplification efficacy of our assay without RNA extraction. Our assay was able to amplify duplex targets of SARS-CoV-2 in one single reaction using one-step RT-MIRA. The assay worked well in a low volume of 10 μl at 38°C for 20 min. Using three collection buffers without guanidinium, our assay was able to amplify efficaciously without RNA extraction. The 95% limit of detection (LoD) of the RT-MIRA assay was 49.5 (95% CI, 46.8–52.7) copies/ml for ORF1ab gene and 48.8 (95% CI, 46.5–52.6) copies/ml for N gene. There is no cross-reaction with other human respiratory pathogens, such as SARS-CoV, MERS-CoV, influenza A virus, influenza B virus, human adenovirus, respiratory syncytial virus, human parainfluenza virus, and coronavirus 229E in our assay. The precision evaluation revealed that the C50−20% to C50+20% range bounds the C5–C95 interval. This assay also showed high anti-interference ability. The extraction-free RT-MIRA and qPCR detection results of 243 nucleic acid specimens from suspected patients or national references showed a 100.0% (95% confidence interval, 94.2%–100.0%) positive predictive value and a 100.0% (95% confidence interval, 92.7%–100.0%) negative predictive value. Compared with qPCR, the kappa value of the two assays was 1.00 (P < 0.0001). In conclusion, we provide a portable and visualized method for detection of SARS-CoV-2 without RNA extraction, allowing its application in SARS-CoV-2 on-site detection.

20 November 2023 in International Journal of Surgery
Verified
Journal Article
Open access
ZSZijian Song
Zijian Song
WZWei Zhang
Wei Zhang
QJQing-Chao Jiang
Qing-Chao Jiang
LDLongxin Deng
Longxin Deng
LDLe Ba Du
Le Ba Du
RCRui Chen
Rui Chen
Background: The early detection of high-grade prostate cancer (HGPCa) is of great importance. However, the current detection strategies result in a high rate of negative biopsies and high medical costs. In this study, the authors aimed to establish an Asian Prostate Cancer Artificial intelligence (APCA) score with no extra cost other than routine health check-ups to predict the risk of HGPCa. Patients and methods: A total of 7476 patients with routine health check-up data who underwent prostate biopsies from January 2008 to December 2021 in eight referral centres in Asia were screened. After data pre-processing and cleaning, 5037 patients and 117 features were analyzed. Seven AI-based algorithms were tested for feature selection and seven AI-based algorithms were tested for classification, with the best combination applied for model construction. The APAC score was established in the CH cohort and validated in a multi-centre cohort and in each validation cohort to evaluate its generalizability in different Asian regions. The performance of the models was evaluated using area under the receiver operating characteristic curve (ROC), calibration plot, and decision curve analyses. Results: Eighteen features were involved in the APCA score predicting HGPCa, with some of these markers not previously used in prostate cancer diagnosis. The area under the curve (AUC) was 0.76 (95% CI:0.74–0.78) in the multi-centre validation cohort and the increment of AUC (APCA vs. PSA) was 0.16 (95% CI:0.13–0.20). The calibration plots yielded a high degree of coherence and the decision curve analysis yielded a higher net clinical benefit. Applying the APCA score could reduce unnecessary biopsies by 20.2% and 38.4%, at the risk of missing 5.0% and 10.0% of HGPCa cases in the multi-centre validation cohort, respectively. Conclusions: The APCA score based on routine health check-ups could reduce unnecessary prostate biopsies without additional examinations in Asian populations. Further prospective population-based studies are warranted to confirm these results.

21 November 2020 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
FWFubo Wang
Fubo Wang
WZWei Zhang
Wei Zhang
ZSZijian Song
Zijian Song
MWMaoyu Wang
Maoyu Wang
HWHanxiao Wu
Hanxiao Wu
RCRui Chen
Rui Chen

23 February 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
HCHui Chen
Hui Chen
WYWanwan Yu
Wanwan Yu
XGXiaojiao Gao
Xiaojiao Gao
WJWeijun Jiang
Weijun Jiang
XLXiaojun Li
Xiaojun Li
YYYang Yang
Yang Yang
Objective: Detecting neutralizing antibodies targeting receptor‐binding domain (RBD) is important for the assessment of humoral protection and vaccine efficacy after vaccination. We compared the performance of three surrogate immunoassays for detection of neutralizing antibodies targeting RBD.Methods: We analyzed 115 serum samples obtained from individuals with Ad5‐vectored COVID‐19 vaccination using two competitive enzyme‐linked immunosorbent assays (Wantai BioPharm and Synthgene Medical Technology) and one competitive chemiluminescence assay (YHLO Biotech). Performance evaluation and methodology comparison were performed according to the Clinical and Laboratory Standards Institute related guidelines.Results: The precision met the manufacturers’ statements. The linear range of the WANTAI was 0.0625–0.545 U/ml and the YHLO was 0.260–242.4 U/ml. The WANTAI’s limit of blank (LoB) and limit of detection (LoD) were 0.03 and 0.06 U/ml, respectively. The YHLO’s LoB and LoD were 0.048 and 0.211 U/ml, respectively. The correlations of semi‐quantitative results of Synthgene with quantitative results of YHLO (ρ = 0.566) and WANTAI (ρ = 0.512) were medium. For YHLO and WANTAI, there was a good agreement (0.62) and a strong correlation (ρ = 0.931). Passing–Bablok analysis and Bland‐Altman plot showed a positive bias (112.3%) of the YHLO compared to the WANTAI. The exclusion of samples >50 U/ml did not decrease bias.Conclusion: These findings contribute to a deeper understanding of surrogate viral neutralization assays and provide useful data for future comparison studies.

1 January 2026 in The Innovation Oncology
Verified
Journal Article
Open access
PDF file
LDLongxin Deng
Longxin Deng
ZSZijian Song
Zijian Song
QZQianwen Zhang
Qianwen Zhang
WZWenhui Zhang
Wenhui Zhang
NTNa Ta
Na Ta
RCRui Chen
Rui Chen
Accurate prediction of homologous recombination deficiency (HRD) status is crucial for effective management of prostate cancer (PCa). However, genetic testing is expensive and inaccessible. We propose a multimodal deep learning approach that integrates clinical information, Hematoxylin & Eosin (H&E)-stained whole-slide images (WSIs), and multiparametric magnetic resonance imaging (MRI) to predict the HRD status of patients with PCa. Patients from The Cancer Genome Atlas (TCGA; n=486) and three Chinese hospitals (n=210) were used to develop and evaluate the prediction models. The Pathology Signature, Radiology Signature, and Patho-Radiology Signature showed predictive performance for HRD status in external validation or internal held-out evaluation (area under the receiver operating characteristic curve [AUC]=0.815, 0.833, and 0.900, respectively). Notably, four interpretable pathological features were identified in the Pathology Signature. These signatures may serve as a prescreening tool to select patients for confirmatory genetic testing. This multimodal framework may be adaptable to the prediction of molecular alterations in other malignancies, subject to independent validation. Because radiology and multimodal models were evaluated in small modality-complete subsets, these estimates should be interpreted as exploratory trends.